Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy Academic Article uri icon

Overview

MeSH Major

  • Depsipeptides
  • Lymphoma, T-Cell, Peripheral
  • Neoplasm Recurrence, Local

abstract

  • Single-agent romidepsin induced complete and durable responses with manageable toxicity in patients with relapsed or refractory PTCL across all major PTCL subtypes, regardless of the number or type of prior therapies. Results led to US Food and Drug Administration approval of romidepsin in this indication.

publication date

  • February 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.37.4223

PubMed ID

  • 22271479

Additional Document Info

start page

  • 631

end page

  • 6

volume

  • 30

number

  • 6